CLINICAL TRIALS PROFILE FOR RUBOXISTAURIN
✉ Email this page to a colleague
Clinical Trials for Ruboxistaurin
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00044395 ↗ | Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes | Completed | Eli Lilly and Company | Phase 3 | The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes. |
| NCT00044408 ↗ | Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes | Completed | Chromaderm, Inc. | Phase 3 | The purpose of this protocol is to determine if an investigational drug known as LY333531 is effective in treating nerve malfunction in diabetes. |
| NCT00044421 ↗ | Treatment of Peripheral Neuropathy in Patients With Diabetes | Completed | Eli Lilly and Company | Phase 3 | The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes. |
| NCT00090519 ↗ | Reduction in the Occurrence of Center-Involved Diabetic Macular Edema | Completed | Chromaderm, Inc. | Phase 3 | The purpose of this study is to determine if ruboxistaurin can help slow the worsening of an eye disease called macular edema in patients with diabetes. |
| NCT00133952 ↗ | Effect of Ruboxistaurin on Clinically Significant Macular Edema | Completed | Chromaderm, Inc. | Phase 3 | The purpose of the study is to test the hypothesis that oral administration of ruboxistaurin will reduce the occurrence of sustained moderate visual loss (SMVL) in patients with clinically significant macular edema. SMVL is defined as a 15 letter or more decrease from baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity that is sustained for the patient's last 6 months of study participation. The SMVL data from this study will be combined with the SMVL data from Study B7A-MC-MBDL for the purpose of comparing ruboxistaurin to placebo. |
| NCT00190970 ↗ | The Effect of Ruboxistaurin on Small Fiber Function | Completed | Chromaderm, Inc. | Phase 2 | To determine the effect of Ruboxistaurin on small fiber function. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Ruboxistaurin
Condition Name
Clinical Trial Locations for Ruboxistaurin
Trials by Country
Clinical Trial Progress for Ruboxistaurin
Clinical Trial Phase
Clinical Trial Sponsors for Ruboxistaurin
Sponsor Name
